Gabapentin Capsule
Product Images NDC 71335-2699

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 71335-2699). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Fig-1 (Gabapentin Fig1)

140 (v ight 40=sgeGeam swesht 08| ;65 2 Femmile peicats 72 x serum creatinine (mg/dL) This text appears to be a mixture of somewhat unclear characters and abbreviations related to numerical values and measurements. It mentions values such as "140," "40," "08," "65," and "72," possibly referring to different measurements or data points. The mention of "serum creatinine (mg/dL)" indicates a measurement related to kidney function. Overall, the text seems to be related to medical data or lab results, but more context would be needed for a precise interpretation.*

FDA Label Image

Figure 1 (Gabapentin Fig2)

The text provides a table displaying the mean pain scores over the course of a specific study or trial involving the administration of a placebo and gabapentin at a dose of 3600 mg/day. The scores are shown for each week from baseline to week 7.*

FDA Label Image

Figure 2 (Gabapentin Fig3)

This is a description related to a pain study comparing different dosages of Gabapentin over a 4-week fixed dose period in comparison to a placebo. The study involves Gabapentin dosages of 1800 mg/day and 2400 mg/day, with the pain scores being evaluated continuously.*

FDA Label Image

Figure 3 (Gabapentin Fig4)

This data represents the proportion of responders (patients with a greater than or equal to 50% reduction in pain score) in controlled Postherpetic Neuralgia (PHN) studies. Study 1 showed 32% of responders in the placebo (PBO) group and 34% in the GBP 3600 group, while Study 2 showed 12% in the placebo group and 14% in the GBP 1800 group. Further analysis is done by comparing the achieved results with statistically significant p-values provided in the text.*

FDA Label Image

Fig-5 (Gabapentin Fig5)

FDA Label Image

Chemical Structure (Gabapentin Str)

FDA Label Image

Label (Lbl713352699)

This text provides information about Gabapentin capsules containing 300 mg of Gabapentin, USP. The capsules come with specific storage instructions and a unique National Drug Code (NDC) for identification. It also mentions the importance of keeping the medication out of reach of children due to potential dizziness side effects. Additionally, it advises scanning the QR code for full prescribing information and indicates that the product is for prescription-only use. The text also includes details of packaging and manufacturing by Bryant Ranch Prepack, Inc. and InvaGen Pharmaceuticals Inc.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.